StockData

BioLineRx vs Rafael

BLRX and RFL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BLRX and RFL compare

Rafael grew revenue faster over the last twelve months (−4.7% versus −95.9% for BioLineRx).

Rafael scores higher on the StockData Score (5 against 3 for BioLineRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBLRXRFL
Size and price
Market cap–$47.7M
Share price$1.12$0.913
Change, 1 year−65.3%−25.1%
Change, 5 years−98.9%−84.5%
Beta (5Y)1.560.58
Employees2017
StockData Score
Total score35 (better)
Valuation score01 (better)
Growth score11
Performance score02 (better)
Health score2 (better)1
Dividend score00
Valuation
P/S–54.5×
P/B–0.7×
FCF yield–−62.9%
Growth
Revenue growth (TTM)−95.9%−4.7% (better)
Revenue growth, 5Y average–1.7%
Profitability
Gross margin80.5%–
Operating margin−872% (better)−3823%
Net margin–−3391%
FCF margin−686% (better)−3431%
Return on equity–−36.9%
Return on invested capital−59.7% (better)−61.5%
Financial health
Debt / equity0.33–
Interest coverage−8.0× (better)−100.3×
Current ratio1.202.35 (better)
Altman Z-score–−2.94
Piotroski F-score–1
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.00%7.5%
Held by insiders0.39%39.2%
Short interest, % of float–0.92%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.